- Home
- MNOV vs GNLX Comparison
MNOV vs GNLX Comparison
Compare MNOV & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | GNLX |
|---|---|---|
| Founded | 2000 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 202.4M |
| IPO Year | 2005 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MNOV | GNLX |
|---|---|---|
| Price | $1.67 | $2.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.00 | ★ $19.75 |
| AVG Volume (30 Days) | 92.5K | ★ 343.2K |
| Earning Date | 02-18-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $257,917.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.13 | $1.99 |
| 52 Week High | $2.06 | $8.54 |
Technical Indicators
Market Signals| Indicator | MNOV | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 67.99 | 34.75 |
| Support Level | $1.43 | $2.52 |
| Resistance Level | $1.72 | $2.80 |
| Average True Range (ATR) | 0.08 | 0.34 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 85.95 | 16.17 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.